litlas
Log inCreate account

Nicholas J. Robert

Active 1984–2024

61
Papers
18,793
Citations
51
h-index
59
i10-index

Citations

Citations per year for Nicholas J. Robert1971: 1 citations1974: 1 citations1984: 1 citations1986: 1 citations1987: 4 citations1988: 2 citations1989: 2 citations1990: 2 citations1991: 5 citations1992: 3 citations1993: 6 citations1994: 13 citations1995: 18 citations1996: 14 citations1997: 29 citations1998: 24 citations1999: 29 citations2000: 42 citations2001: 74 citations2002: 89 citations2003: 91 citations2004: 89 citations2005: 102 citations2006: 99 citations2007: 144 citations2008: 145 citations2009: 130 citations2010: 144 citations2011: 133 citations2012: 145 citations2013: 137 citations2014: 116 citations2015: 119 citations2016: 118 citations2017: 123 citations2018: 116 citations2019: 388 citations2020: 373 citations2021: 353 citations2022: 297 citations2023: 214 citations2024: 326 citations2025: 137 citations1972–1973: no citations, so these years are not shown1975–1983: no citations, so these years are not shown1985: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,915 citing papers, 28.7% of this breakdownUnited Kingdom: 441 citing papers, 6.6% of this breakdownItaly: 386 citing papers, 5.8% of this breakdownChina: 381 citing papers, 5.7% of this breakdownGermany: 320 citing papers, 4.8% of this breakdownCanada: 304 citing papers, 4.6% of this breakdownSpain: 260 citing papers, 3.9% of this breakdownFrance: 243 citing papers, 3.6% of this breakdownSwitzerland: 212 citing papers, 3.2% of this breakdownBelgium: 190 citing papers, 2.8% of this breakdownAustralia: 180 citing papers, 2.7% of this breakdownJapan: 152 citing papers, 2.3% of this breakdown
0%28.7%Other 25.3%

Institutions

Fields

  • Medicine62.1%
  • Biochemistry, Genetics and Molecular Biology30.1%
  • Immunology and Microbiology1.8%
  • Materials Science1.3%
  • Computer Science0.8%
  • Nursing0.7%
  • Other3.2%

Topics

  • HER2/EGFR in Cancer Research12.1%
  • Breast Cancer Treatment Studies9.9%
  • Cancer Treatment and Pharmacology5.3%
  • Advanced Breast Cancer Therapies4.8%
  • Monoclonal and Polyclonal Antibodies Research4.7%
  • Estrogen and related hormone effects2.7%
  • Other60.5%

Coauthors

All papers

Open in search
  1. Adjuvant Trastuzumab in HER2-Positive Breast Cancer

    Authors: Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown - New England Journal of Medicine 2011 cited by 2,775

  2. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

    Authors: Jeremy Braybrooke, Rosie Bradley, Richard Gray, Robert K. Hills, Hongchao Pan, Richárd Pető, David Dodwell, Paul McGale, Carolyn Taylor, Tomohiko Aihara, Stewart Anderson, Joanne L. Blum, Fátima Cardoso, Xiaosong Chen, John Crown, Bent Ejlertsen, Thomas W. P. Friedl, Nadia Harbeck, Wolfgang Janni, Maj‐Britt Jensen, E. Mamounas, Kazutaka Narui, Ulrike Nitz, Larry Norton, Joyce O’Shaughnessy, Martine Piccart, Nicholas J. Robert, Zhi‐Ming Shao, Dennis Slamon, Joseph A. Sparano, Toru Watanabe, Greg Yothers, Ke‐Da Yu, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Lucy Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Lui, Zulian Lui, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Aman U. Buzdar, Vera J. Suman, Kelly K. Hunt, Robert Leonard, Janine Mansi, Catherine Delbaldo, Pascal Piedbois, Emmanuel Quinaux, Christian Fesl, Michael Gnant, Lidija Sölkner, Guenther G. Steger, Hans Petter Eikesdal, Per Eystein Lønning, Valerie Bée, Helena Fung, John R. Mackey, Miguel Martín, Michael F. Press, Evandro de Azambuja, Richard D. Gelber, Meredith M. Regan, Angelo Di Leo, Veerle Van Dooren, J.-M. Nogaret, John M.S. Bartlett, Bingshu E. Chen, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Kathleen I. Pritchard, Lois E. Shepherd, Donald A. Berry, Constance Cirrincione, Lawrence N. Shulman, Eric P. Winer, Rebecca Gelman, Jay R. Harris, Craig Henderson, Charles L. Shapiro, Peer Christiansen, Marianne Ewertz, Henning T. Mouridsen, Elise Van Leeuwen, Sabine C. Linn, Annelot G.J. van Rossum, Harm van Tinteren and 136 more - The Lancet 2023 cited by 189

  3. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, Erhan Gökmen, Anna Bashford, Manuel Ruíz Borrego, Sung‐Bae Kim, Erik Jakobsen, A. Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B. Heijns, Anne Armstrong, John S. Link, Anil A. Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz and 526 more - The Lancet Oncology 2017 cited by 589

  4. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Authors: Paul E. Goss, James N. Ingle, Kathleen I. Pritchard, Nicholas J. Robert, Hyman B. Muss, Julie R. Gralow, Karen A. Gelmon, Timothy J. Whelan, Kathrin Strasser‐Weippl, S. Rubin, Keren Sturtz, Antonio C. Wolff, Eric P. Winer, Clifford A. Hudis, Alison Stopeck, J. Thaddeus Beck, Judith S. Kaur, Kate Whelan, Dongsheng Tu, Wendy R. Parulekar - New England Journal of Medicine 2016 cited by 648

  5. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Arlene Chan, Suzette Delaloge, Frankie A. Holmes, Beverly Moy, Hiroji Iwata, Vernon Harvey, Nicholas J. Robert, Tajana Silovski, Erhan Gökmen, Gϋnter von Minckwitz, Bent Ejlertsen, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Marc Buyse, Ira Gore, John W. Smith, Graydon Harker, Norikazu Masuda, Katarína Petráková, Ángel Guerrero Zotano, Nicholas Iannotti, Gladys Rodriguez, Pierfrancesco Tassone, Alvin Wong, Richard Bryce, Yining Ye, Bin Yao, Miguel Martín - The Lancet Oncology 2016 cited by 565

  6. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Authors: Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy - Journal of Clinical Oncology 2011 cited by 1,061

  7. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network

    Authors: Nicholas J. Robert, Janet L. Espirito, Liwei Chen, Esmond Nwokeji, Mandar Karhade, Makenzi Colleen Evangelist, Alexander I. Spira, Marcus A. Neubauer, Susie Bullock, Jennifer Walberg, Steven K. Cheng, Robert L. Coleman - Lung Cancer 2022 cited by 80

  8. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

    Authors: Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Nicholas J. Robert, Suzy Scholl, Louis Fehrenbacher, Janet Wolter, Virginia Paton, Steven Shak, Gracie Lieberman, Dennis J. Slamon - Journal of Clinical Oncology 1999 cited by 2,790

  9. Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

    Authors: Joanne L. Blum, Patrick J. Flynn, Greg Yothers, Lina Asmar, Charles E. Geyer, Samuel A. Jacobs, Nicholas J. Robert, Judith O. Hopkins, Joyce O’Shaughnessy, Chau T. Dang, Henry Gómez, Louis Fehrenbacher, Svetislava J. Vukelja, Alan P. Lyss, Devchand Paul, Adam Brufsky, Jong‐Hyeon Jeong, Linda H. Colangelo, Sandra M. Swain, Eleftherios P. Mamounas, Stephen E. Jones, Norman Wolmark - Journal of Clinical Oncology 2017 cited by 288

  10. Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era

    Authors: Neil J. Shah, Sneha Sura, Reshma Shinde, Junxin Shi, Puneet K. Singhal, Nicholas J. Robert, Nicholas J. Vogelzang, Rodolfo F. Perini, Robert J. Motzer - European Urology Open Science 2023 cited by 58

  11. The Friends of Cancer Research Real‐World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies

    Authors: Donna R. Rivera, Henry J. Henk, Elizabeth Garrett‐Mayer, Jennifer Christian, Andrew J. Belli, Suanna S. Bruinooge, Janet L. Espirito, Connor Sweetnam, Monika A. Izano, Yanina Natanzon, Nicholas J. Robert, Mark S. Walker, Aaron B. Cohen, Marley Boyd, Lindsey Enewold, Eric Hansen, Rebecca Honnold, Lawrence H. Kushi, P Kalyani, Ruth Pe Benito, Lori C. Sakoda, Elad Sharon, Olga Tymejczyk, Emily Valice, Joseph Wagner, Laura Lasiter, Jeff Allen - Clinical Pharmacology & Therapeutics 2021 cited by 56

  12. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Authors: Paul E. Goss, James N. Ingle, Silvana Martino, Nicholas J. Robert, Hyman B. Muss, Martine Piccart, Monica Castiglione, Dongsheng Tu, Lois E. Shepherd, Kathleen I. Pritchard, Robert B. Livingston, Nancy E. Davidson, Larry Norton, Edith A. Perez, Jeffrey S. Abrams, David Cameron, Michael Palmer, Joseph L. Pater - JNCI Journal of the National Cancer Institute 2005 cited by 1,120

  13. Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer

    Authors: Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich, Sara A. Byron, Stephen P. Anthony, Nicholas J. Robert, Donald W. Northfelt, Mohammad Jahanzeb, Linda Vocila, Julia Wulfkuhle, Guido Gambara, Rosa I. Gallagher, Bryant Dunetz, Nicholas N Hoke, Ting Dong, David W. Craig, Massimo Cristofanilli, Brian Leyland‐Jones, Lance A. Liotta, Joyce O’Shaughnessy, John D. Carpten, Emanuel F. Petricoin - Clinical Cancer Research 2017 cited by 96

  14. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy

    Authors: C. Lance Cowey, Nicholas J. Robert, Janet L. Espirito, Kalatu Davies, Jennifer R. Frytak, Israel Lowy, Matthew G. Fury - Cancer Medicine 2020 cited by 54

  15. Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists

    Authors: David Waterhouse, Wan-Yu Tseng, Janet L. Espirito, Nicholas J. Robert - Clinical Lung Cancer 2021 cited by 29

  16. Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

    Authors: Joyce O’Shaughnessy, Lee Schwartzberg, Michael A. Danso, Kathy D. Miller, Hope S. Rugo, Marcus A. Neubauer, Nicholas J. Robert, Beth A. Hellerstedt, Mansoor N. Saleh, Paul Richards, Jennifer M. Specht, Denise A. Yardley, Robert W. Carlson, Richard S. Finn, Éric Charpentier, Ignacio Garcia‐Ribas, Eric P. Winer - Journal of Clinical Oncology 2014 cited by 305

  17. Comparisons of Real-World Time-to-Event End Points in Oncology Research

    Authors: Brigham Walker, Marley Boyd, Kat Aguilar, Kalatu Davies, Janet L. Espirito, Jennifer R. Frytak, Nicholas J. Robert - JCO Clinical Cancer Informatics 2021 cited by 64

  18. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

    Authors: Valentina Guarneri, David Miles, Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran, PierFranco Conte - Breast Cancer Research and Treatment 2010 cited by 285

  19. Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy

    Authors: Michael F. Press, Guido Sauter, Marc Buyse, Leslie Bernstein, Roberta Guzman, Angela Santiago, Ivonne Villalobos, W. Eiermann, Tadeusz Pieńkowski, Miguel Martín, Nicholas J. Robert, John Crown, Valerie Bée, Henry Taupin, Kerry Flom, Isabelle Tabah-Fisch, Giovanni M. Pauletti, Mark A. Lindsay, A. Riva, Dennis J. Slamon - Journal of Clinical Oncology 2010 cited by 220

  20. Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group

    Authors: Amyé Tevaarwerk, Μolin Wang, Fengmin Zhao, John H. Fetting, David Cella, Lynne I. Wagner, Silvana Martino, James N. Ingle, Joseph A. Sparano, Lawrence J. Solin, William C. Wood, Nicholas J. Robert - Journal of Clinical Oncology 2014 cited by 148

  21. Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

    Authors: Sara A. Hurvitz, David J. Betting, Howard M. Stern, Emmanuel Quinaux, Jeremy Stinson, Somasekar Seshagiri, Ying Zhao, Marc Buyse, John R. Mackey, Adrian Driga, Sambasivarao Damaraju, Mark X. Sliwkowski, Nicholas J. Robert, Vicente Valero, John Crown, Carla I. Falkson, Adam Brufsky, Tadeusz Pieńkowski, W. Eiermann, Miguel Martín, Valerie Bée, Omkar Marathe, Dennis J. Slamon, John M. Timmerman - Clinical Cancer Research 2012 cited by 111

  22. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])

    Authors: Charles E. Geyer, Joanne L. Blum, Greg Yothers, Lina Asmar, Patrick J. Flynn, Nicholas J. Robert, Judith O. Hopkins, Joyce O’Shaughnessy, Priya Rastogi, Shannon L. Puhalla, Christie Hilton, Chau T. Dang, Henry L. Gómez, Svetislava J. Vukelja, Alan P. Lyss, Devchand Paul, Adam Brufsky, Linda H. Colangelo, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2024 cited by 22

  23. Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes

    Authors: Joanne L. Blum, Michael A. Savin, Gerald M. Edelman, John Pippen, Nicholas J. Robert, Brian V. Geister, Robert Kirby, Alicia Clawson, Joyce O’Shaughnessy - Clinical Breast Cancer 2007 cited by 178

  24. Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy

    Authors: Jerome H. Goldschmidt, Lin‐Na Chou, Philip K. Chan, Liwei Chen, Nicholas J. Robert, Joyce Kinsey, Katherine Pitts, Matt Nestor, Edwin P. Rock, Hillard M. Lazarus - Cancer Medicine 2023 cited by 26